Deciphering antibody-mediated rejection: New insights into mechanisms and treatment

Mark D Stegall, James M. Gloor

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Purpose of review: To outline recent studies describing the mechanisms of antibody-mediated rejection (AMR) and new clinical protocols aimed at prevention and/or treatment of this difficult clinical entity. Recent findings: The natural history of acute AMR after positive cross-match kidney transplantation involves an acute rise in donor-specific alloantibody (DSA) in the first few weeks after transplantation. Whereas the exact cellular mechanisms responsible for AMR are not known, it seems likely that both pre-existing plasma cells and the conversion of memory B cells to new plasma cells play a role in the increased DSA production. One recent study suggested that combination therapy with plasmapheresis, high-dose IVIG and rituximab was more effective treatment for AMR than high-dose intravenous immunoglobulin (IVIG) alone, but the role of anti-CD20 antibody is still unclear. Two new promising approaches to AMR focus on depletion of plasma cells with the proteasome inhibitor, bortezomib, and the inhibition of terminal complement activation with a humanized, anti-C5 antibody, eculizumab. Summary: The pathogenesis of AMR in several different clinical settings is becoming clearer and more effective treatments are being developed. Whether the prevention or successful treatment of AMR will decrease the prevalence of chronic injury and improved long-term graft survival will require longer-term studies.

Original languageEnglish (US)
Pages (from-to)8-10
Number of pages3
JournalCurrent Opinion in Organ Transplantation
Volume15
Issue number1
DOIs
StatePublished - Feb 2010

Fingerprint

Antibodies
Plasma Cells
Isoantibodies
Intravenous Immunoglobulins
Therapeutics
Anti-Idiotypic Antibodies
Proteasome Inhibitors
Plasmapheresis
Complement Activation
Graft Survival
Clinical Protocols
Natural History
Kidney Transplantation
B-Lymphocytes
Transplantation
Wounds and Injuries

Keywords

  • Alloantibody
  • Antibody-mediated rejection
  • Highly sensitized patient
  • Kidney transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

Deciphering antibody-mediated rejection : New insights into mechanisms and treatment. / Stegall, Mark D; Gloor, James M.

In: Current Opinion in Organ Transplantation, Vol. 15, No. 1, 02.2010, p. 8-10.

Research output: Contribution to journalArticle

@article{1469bac0f1464d0b82ca59dec2bb4bac,
title = "Deciphering antibody-mediated rejection: New insights into mechanisms and treatment",
abstract = "Purpose of review: To outline recent studies describing the mechanisms of antibody-mediated rejection (AMR) and new clinical protocols aimed at prevention and/or treatment of this difficult clinical entity. Recent findings: The natural history of acute AMR after positive cross-match kidney transplantation involves an acute rise in donor-specific alloantibody (DSA) in the first few weeks after transplantation. Whereas the exact cellular mechanisms responsible for AMR are not known, it seems likely that both pre-existing plasma cells and the conversion of memory B cells to new plasma cells play a role in the increased DSA production. One recent study suggested that combination therapy with plasmapheresis, high-dose IVIG and rituximab was more effective treatment for AMR than high-dose intravenous immunoglobulin (IVIG) alone, but the role of anti-CD20 antibody is still unclear. Two new promising approaches to AMR focus on depletion of plasma cells with the proteasome inhibitor, bortezomib, and the inhibition of terminal complement activation with a humanized, anti-C5 antibody, eculizumab. Summary: The pathogenesis of AMR in several different clinical settings is becoming clearer and more effective treatments are being developed. Whether the prevention or successful treatment of AMR will decrease the prevalence of chronic injury and improved long-term graft survival will require longer-term studies.",
keywords = "Alloantibody, Antibody-mediated rejection, Highly sensitized patient, Kidney transplantation",
author = "Stegall, {Mark D} and Gloor, {James M.}",
year = "2010",
month = "2",
doi = "10.1097/MOT.0b013e3283342712",
language = "English (US)",
volume = "15",
pages = "8--10",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Deciphering antibody-mediated rejection

T2 - New insights into mechanisms and treatment

AU - Stegall, Mark D

AU - Gloor, James M.

PY - 2010/2

Y1 - 2010/2

N2 - Purpose of review: To outline recent studies describing the mechanisms of antibody-mediated rejection (AMR) and new clinical protocols aimed at prevention and/or treatment of this difficult clinical entity. Recent findings: The natural history of acute AMR after positive cross-match kidney transplantation involves an acute rise in donor-specific alloantibody (DSA) in the first few weeks after transplantation. Whereas the exact cellular mechanisms responsible for AMR are not known, it seems likely that both pre-existing plasma cells and the conversion of memory B cells to new plasma cells play a role in the increased DSA production. One recent study suggested that combination therapy with plasmapheresis, high-dose IVIG and rituximab was more effective treatment for AMR than high-dose intravenous immunoglobulin (IVIG) alone, but the role of anti-CD20 antibody is still unclear. Two new promising approaches to AMR focus on depletion of plasma cells with the proteasome inhibitor, bortezomib, and the inhibition of terminal complement activation with a humanized, anti-C5 antibody, eculizumab. Summary: The pathogenesis of AMR in several different clinical settings is becoming clearer and more effective treatments are being developed. Whether the prevention or successful treatment of AMR will decrease the prevalence of chronic injury and improved long-term graft survival will require longer-term studies.

AB - Purpose of review: To outline recent studies describing the mechanisms of antibody-mediated rejection (AMR) and new clinical protocols aimed at prevention and/or treatment of this difficult clinical entity. Recent findings: The natural history of acute AMR after positive cross-match kidney transplantation involves an acute rise in donor-specific alloantibody (DSA) in the first few weeks after transplantation. Whereas the exact cellular mechanisms responsible for AMR are not known, it seems likely that both pre-existing plasma cells and the conversion of memory B cells to new plasma cells play a role in the increased DSA production. One recent study suggested that combination therapy with plasmapheresis, high-dose IVIG and rituximab was more effective treatment for AMR than high-dose intravenous immunoglobulin (IVIG) alone, but the role of anti-CD20 antibody is still unclear. Two new promising approaches to AMR focus on depletion of plasma cells with the proteasome inhibitor, bortezomib, and the inhibition of terminal complement activation with a humanized, anti-C5 antibody, eculizumab. Summary: The pathogenesis of AMR in several different clinical settings is becoming clearer and more effective treatments are being developed. Whether the prevention or successful treatment of AMR will decrease the prevalence of chronic injury and improved long-term graft survival will require longer-term studies.

KW - Alloantibody

KW - Antibody-mediated rejection

KW - Highly sensitized patient

KW - Kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=75749083746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749083746&partnerID=8YFLogxK

U2 - 10.1097/MOT.0b013e3283342712

DO - 10.1097/MOT.0b013e3283342712

M3 - Article

C2 - 19890210

AN - SCOPUS:75749083746

VL - 15

SP - 8

EP - 10

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 1

ER -